Drug discovery

reMYND’s research & development aims to discover and develop disease-modifying drugs for the treatment of patients suffering protein-misfolding diseases comprising different disease areas.

At the heart of our drug discovery technology platform are functional screens recapitulating noxious properties of pathological protein aggregation. Candidate drugs are extensively characterised in-vivo using our internal collection of proprietary transgenic mouse models.

Currently a rich pipeline of products is being pursued.